DE102019121007A1 - Antigenbindende Proteine, die spezifisch an MAGE-A binden - Google Patents

Antigenbindende Proteine, die spezifisch an MAGE-A binden Download PDF

Info

Publication number
DE102019121007A1
DE102019121007A1 DE102019121007.0A DE102019121007A DE102019121007A1 DE 102019121007 A1 DE102019121007 A1 DE 102019121007A1 DE 102019121007 A DE102019121007 A DE 102019121007A DE 102019121007 A1 DE102019121007 A1 DE 102019121007A1
Authority
DE
Germany
Prior art keywords
amino acid
seq
acid sequence
variable domain
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE102019121007.0A
Other languages
German (de)
English (en)
Inventor
Martin Hofmann
Felix Unverdorben
Meike Hutt
Gabriele Pszolla
Dominik Maurer
Sebastian Bunk
Sara Yousef
Claudia Wagner
Frank Schwöbel
Heiko Schuster
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immatics Biotechnologies GmbH
Original Assignee
Immatics Biotechnologies GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies GmbH filed Critical Immatics Biotechnologies GmbH
Priority to DE102019121007.0A priority Critical patent/DE102019121007A1/de
Priority to US16/943,779 priority patent/US11840577B2/en
Priority to PE2022000179A priority patent/PE20221021A1/es
Priority to TW109125935A priority patent/TWI878330B/zh
Priority to KR1020227006480A priority patent/KR20220041161A/ko
Priority to CN202080055666.0A priority patent/CN114616244A/zh
Priority to CN202210924728.8A priority patent/CN115925958A/zh
Priority to PCT/EP2020/071660 priority patent/WO2021023658A1/en
Priority to CA3148937A priority patent/CA3148937A1/en
Priority to EP20751505.7A priority patent/EP4007776A1/en
Priority to JP2022506617A priority patent/JP7476298B2/ja
Priority to CR20220086A priority patent/CR20220086A/es
Priority to PH1/2022/550230A priority patent/PH12022550230A1/en
Priority to AU2020324515A priority patent/AU2020324515A1/en
Priority to BR112022001923A priority patent/BR112022001923A2/pt
Priority to MX2022001422A priority patent/MX2022001422A/es
Priority to ARP200103306A priority patent/AR120585A1/es
Publication of DE102019121007A1 publication Critical patent/DE102019121007A1/de
Priority to IL290268A priority patent/IL290268A/en
Priority to CL2022000252A priority patent/CL2022000252A1/es
Priority to MX2022011410A priority patent/MX2022011410A/es
Priority to MX2022011411A priority patent/MX2022011411A/es
Priority to CONC2022/0002044A priority patent/CO2022002044A2/es
Priority to CL2023000562A priority patent/CL2023000562A1/es
Priority to US18/483,174 priority patent/US20240052054A1/en
Priority to US18/538,242 priority patent/US12269881B2/en
Priority to JP2024066707A priority patent/JP2024105296A/ja
Priority to US19/050,553 priority patent/US20250215084A1/en
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE102019121007.0A 2019-08-02 2019-08-02 Antigenbindende Proteine, die spezifisch an MAGE-A binden Pending DE102019121007A1 (de)

Priority Applications (27)

Application Number Priority Date Filing Date Title
DE102019121007.0A DE102019121007A1 (de) 2019-08-02 2019-08-02 Antigenbindende Proteine, die spezifisch an MAGE-A binden
US16/943,779 US11840577B2 (en) 2019-08-02 2020-07-30 Antigen binding proteins specifically binding MAGE-A
AU2020324515A AU2020324515A1 (en) 2019-08-02 2020-07-31 Antigen binding proteins specifically binding MAGE-A
MX2022001422A MX2022001422A (es) 2019-08-02 2020-07-31 Proteinas de union a antigeno que se unen especificamente a mage-a.
KR1020227006480A KR20220041161A (ko) 2019-08-02 2020-07-31 Mage-a에 특이적으로 결합하는 항원 결합 단백질
CN202080055666.0A CN114616244A (zh) 2019-08-02 2020-07-31 特异性结合mage-a的抗原结合蛋白
CN202210924728.8A CN115925958A (zh) 2019-08-02 2020-07-31 特异性结合mage-a的抗原结合蛋白
PCT/EP2020/071660 WO2021023658A1 (en) 2019-08-02 2020-07-31 Antigen binding proteins specifically binding mage-a
CA3148937A CA3148937A1 (en) 2019-08-02 2020-07-31 Antigen binding proteins specifically binding mage-a
EP20751505.7A EP4007776A1 (en) 2019-08-02 2020-07-31 Antigen binding proteins specifically binding mage-a
JP2022506617A JP7476298B2 (ja) 2019-08-02 2020-07-31 Ｍａｇｅ－ａに特異的に結合する抗原結合タンパク質
CR20220086A CR20220086A (es) 2019-08-02 2020-07-31 Proteínas de unión a antígeno que se unen específicamente a mage-a
PH1/2022/550230A PH12022550230A1 (en) 2019-08-02 2020-07-31 Antigen binding proteins specifically binding mage-a
PE2022000179A PE20221021A1 (es) 2019-08-02 2020-07-31 Proteinas de union a antigeno que se unen especificamente a mage-a
BR112022001923A BR112022001923A2 (pt) 2019-08-02 2020-07-31 Proteína de ligação ao antígeno, ácido nucleico isolado, célula hospedeira recombinante, composição farmacêutica, método de produção da proteína de ligação ao antígeno
TW109125935A TWI878330B (zh) 2019-08-02 2020-07-31 特異性結合mage-a的抗原結合蛋白
ARP200103306A AR120585A1 (es) 2019-08-02 2020-11-27 Proteínas de unión a antígenos que se unen específicamente a mage-a
IL290268A IL290268A (en) 2019-08-02 2022-01-31 Antigen binding proteins that specifically bind mage-a
CL2022000252A CL2022000252A1 (es) 2019-08-02 2022-01-31 Proteínas de unión a antígeno que se unen específicamente a mage-a
MX2022011410A MX2022011410A (es) 2019-08-02 2022-02-01 Proteinas de union a antigeno que se unen especificamente a mage-a.
MX2022011411A MX2022011411A (es) 2019-08-02 2022-02-01 Proteinas de union a antigeno que se unen especificamente a mage-a.
CONC2022/0002044A CO2022002044A2 (es) 2019-08-02 2022-02-25 Proteínas de unión a antígeno que se unen específicamente a mage-a
CL2023000562A CL2023000562A1 (es) 2019-08-02 2023-02-27 Proteínas de unión a antígeno que se unen específicamente a mage-a
US18/483,174 US20240052054A1 (en) 2019-08-02 2023-10-09 Antigen binding proteins specifically binding mage-a
US18/538,242 US12269881B2 (en) 2019-08-02 2023-12-13 Antigen binding proteins specifically binding MAGE-A
JP2024066707A JP2024105296A (ja) 2019-08-02 2024-04-17 Ｍａｇｅ－ａに特異的に結合する抗原結合タンパク質
US19/050,553 US20250215084A1 (en) 2019-08-02 2025-02-11 Antigen binding proteins specifically binding mage-a

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102019121007.0A DE102019121007A1 (de) 2019-08-02 2019-08-02 Antigenbindende Proteine, die spezifisch an MAGE-A binden

Publications (1)

Publication Number Publication Date
DE102019121007A1 true DE102019121007A1 (de) 2021-02-04

Family

ID=74165587

Family Applications (1)

Application Number Title Priority Date Filing Date
DE102019121007.0A Pending DE102019121007A1 (de) 2019-08-02 2019-08-02 Antigenbindende Proteine, die spezifisch an MAGE-A binden

Country Status (19)

Country Link
US (4) US11840577B2 (https=)
EP (1) EP4007776A1 (https=)
JP (2) JP7476298B2 (https=)
KR (1) KR20220041161A (https=)
CN (2) CN115925958A (https=)
AR (1) AR120585A1 (https=)
AU (1) AU2020324515A1 (https=)
BR (1) BR112022001923A2 (https=)
CA (1) CA3148937A1 (https=)
CL (2) CL2022000252A1 (https=)
CO (1) CO2022002044A2 (https=)
CR (1) CR20220086A (https=)
DE (1) DE102019121007A1 (https=)
IL (1) IL290268A (https=)
MX (3) MX2022001422A (https=)
PE (1) PE20221021A1 (https=)
PH (1) PH12022550230A1 (https=)
TW (1) TWI878330B (https=)
WO (1) WO2021023658A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023148494A1 (en) * 2022-02-03 2023-08-10 University College Cardiff Consultants Limited Novel t-cell receptor
US20230365649A1 (en) * 2020-10-02 2023-11-16 The Usa, As Represented By The Secretary, Department Of Health And Human Services Hla class ii-restricted dq t cell receptors against ras with g13d mutation

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3428194T (lt) 2017-07-14 2021-12-10 Immatics Biotechnologies Gmbh Pagerinta dvejopo savitumo polipeptido molekulė
DE102019121007A1 (de) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
US12435444B2 (en) 2021-03-09 2025-10-07 Cdr-Life Ag Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same
MX2023010541A (es) 2021-03-09 2023-11-24 Cdr Life Ag Proteinas de union al antigeno del peptido del mhc mage-a4.
WO2022233956A1 (en) 2021-05-05 2022-11-10 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
IL308258A (en) * 2021-05-05 2024-01-01 Immatics Biotechnologies Gmbh Bma031 antigen binding polypeptides
EP4091627A1 (en) 2021-05-21 2022-11-23 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Tcr constructs specific for magea4-derived epitopes
WO2023099606A1 (en) 2021-12-01 2023-06-08 Immunocore Limited Treatment of mage-a4 positive cancer
CN114457002B (zh) * 2022-02-23 2023-08-22 中山大学 一种分离细胞外囊泡亚群的方法及其应用
WO2023215183A1 (en) * 2022-05-02 2023-11-09 Tscan Therapeutics, Inc. Multiplexed t cell receptor compositions, combination therapies, and uses thereof
EP4534554A1 (en) * 2022-06-01 2025-04-09 Corregene Biotechnology Co., Ltd. Mage-a1 specific tcr and use thereof
JP2025525382A (ja) * 2022-06-24 2025-08-05 アムジエン・インコーポレーテツド Ｍａｇｅａ４特異的ｔ細胞受容体
WO2024035962A2 (en) * 2022-08-12 2024-02-15 Ingenious Targeting Laboratories Genetically modified non-human having humanized gamma and delta tcr variable genes
CA3264474A1 (en) 2022-09-14 2024-03-21 Cdr-Life Ag MAGE-A4 DOUBLE T LYMPHOCYTE ENGAGEMENT
AU2024214482A1 (en) 2023-02-03 2025-08-07 Zelluna Immunotherapy As Anti-mage-a4 t cell receptors
CN116519936B (zh) * 2023-02-28 2025-11-07 杭州凯保罗生物科技有限公司 用于前列腺癌早期检测的肿瘤自身抗原/抗体组合及应用
CN121358777A (zh) 2023-07-27 2026-01-16 伊玛提克斯生物技术有限公司 抗mageb2的抗原结合蛋白
WO2025233432A1 (en) 2024-05-07 2025-11-13 Immatics Biotechnologies Gmbh Use and dosage of an antigen-binding protein comprising a tcr specific for an hla-a*02 restricted peptide
WO2025233431A1 (en) 2024-05-07 2025-11-13 Immatics Biotechnologies Gmbh Heteromeric proteins comprising three heteromerization improving substitution, production, combinations and applications thereof
GB2641580A (en) 2024-06-07 2025-12-10 T Therapeutics Ltd Tumour-transforming multispecific proteins
WO2026008886A1 (en) 2024-07-05 2026-01-08 Immatics Biotechnologies Gmbh Means and methods for the quantification of target expression
WO2026025031A1 (en) 2024-07-26 2026-01-29 Modernatx, Inc. Mrna encoding mageb2 tcer molecule
WO2026078231A1 (en) 2024-10-11 2026-04-16 T-Therapeutics Limited Soluble non-aggregating immune ligand
WO2026082746A1 (en) 2024-10-14 2026-04-23 Immatics Biotechnologies Gmbh Bispecific molecule formulation
CN119529098B (zh) * 2025-01-22 2025-05-30 北京可瑞生物科技有限公司 对mage-a1具有特异性的结合分子和抗cd3的融合蛋白

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4179338A (en) 1977-09-19 1979-12-18 Gordon Maurice R Microbiological medium suitable for sterilization by ionizing radiation
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
DE69434860T2 (de) 1993-02-22 2007-03-15 The Rockefeller University Herstellung von helfer-freien retroviren mit hohem titer mittels transienter transfektion
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
ES2233974T3 (es) 1995-09-11 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Anticuerpo contra la cadena alfa del receptor de la interleucina 5 humana.
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
CA2243235C (en) 1996-01-17 2010-08-10 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
MXPA02005559A (es) 1999-12-06 2004-09-10 Univ Illinois Proteinas de tcr de alta afinidad y metodos.
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
DE10225139A1 (de) 2002-05-29 2004-02-26 Immatics Biotechnologies Gmbh Verfahren zur Identifizierung von immunreaktiven Peptiden
PT1558643E (pt) 2002-11-09 2009-08-24 Immunocore Ltd Apresentação de um receptor das células t
GB0308731D0 (en) 2003-04-15 2003-05-21 Anticancer Therapeutic Inv Sa Method of radiotherapy
WO2005076009A2 (en) 2004-01-28 2005-08-18 Immatics Biotechnologies Gmbh Method for identifying and quantifying of tumour-associated peptides
US9963510B2 (en) * 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
JP5276846B2 (ja) 2005-09-13 2013-08-28 国立大学法人三重大学 Ｔ細胞レセプターをコードする核酸が挿入されてなるベクター及び該レセプターを発現する細胞
WO2008053573A1 (fr) 2006-10-30 2008-05-08 National University Corporation Hokkaido University Remède pour néoplasme malin
MX338397B (es) 2007-08-29 2016-04-15 Sanofi Aventis Anticuerpos anti - cxcr5 humanizados, derivados de los mismos y su uso.
KR101680906B1 (ko) 2007-09-26 2016-11-30 추가이 세이야쿠 가부시키가이샤 항체 정상영역 개변체
EP2337795A2 (en) 2008-10-01 2011-06-29 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
US9840695B2 (en) 2009-04-28 2017-12-12 Agriculture Victoria Services Pty Ltd Plant technology
EP2258719A1 (en) 2009-05-19 2010-12-08 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Multiple target T cell receptor
EP2486049A1 (en) 2009-10-06 2012-08-15 The Board Of Trustees Of The UniversityOf Illinois Human single-chain t cell receptors
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
HRP20171164T1 (hr) 2010-09-20 2017-10-20 Biontech Cell & Gene Therapies Gmbh Antigen-specifični t stanični receptori i t stanični epitopi
TWI743461B (zh) 2011-03-28 2021-10-21 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
WO2013026837A1 (en) 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
AU2012302778B2 (en) 2011-08-31 2016-11-24 Mie University Vaccine preparation for cancer treatment
WO2013048243A1 (en) * 2011-09-29 2013-04-04 Apo-T B.V. Multi-specific binding molecules targeting aberrant cells
WO2013057596A1 (en) 2011-10-21 2013-04-25 Atena Srl Anatomic cushion accumulator for thermal treatment with heat or cold
EP2660250B1 (en) 2012-05-02 2018-11-14 Deutsches Rheuma-Forschungszentrum Berlin Tcr transgenic mouse model for immune disease
KR102499753B1 (ko) 2012-07-27 2023-02-16 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 Ｔ 세포 수용체 조작
KR102480188B1 (ko) * 2012-09-14 2022-12-21 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 Mhc ii형 제한된 mage-a3을 인식하는 t 세포 수용체
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
SMT202100464T1 (it) 2013-03-14 2021-11-12 Macrogenics Inc Molecole bispecifiche che sono immunoreattive con cellule effettrici immunitarie che esprimono un recettore di attivazione
US11634502B2 (en) 2013-03-15 2023-04-25 Amgen Inc. Heterodimeric bispecific antibodies
AU2014301777B2 (en) 2013-06-26 2017-03-30 Xlifesc, Ltd. High-stability T-cell receptor and preparation method and application thereof
US11203783B2 (en) 2013-11-21 2021-12-21 Repertoire Genesis Incorporation T cell receptor and B cell receptor repertoire analysis system, and use of same in treatment and diagnosis
IL263466B2 (en) 2013-12-17 2023-10-01 Genentech Inc Anti-CD3 antibodies and methods of using them
US10202640B2 (en) 2014-05-07 2019-02-12 The Board Of Trustees Of The Leland Stanford Junior University Single cell analysis of T cells using high-throughput multiplex amplification and deep sequencing
EP2985294A1 (en) 2014-08-14 2016-02-17 Deutsches Krebsforschungszentrum Recombinant antibody molecule and its use for target cell restricted T cell activation
GB201423361D0 (en) 2014-12-30 2015-02-11 Immatics Biotechnologies Gmbh Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
CN120988137A (zh) 2015-01-23 2025-11-21 赛诺菲 抗cd3抗体、抗cd123抗体和与cd3和/或cd123特异性结合的双特异性抗体
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
GB201506642D0 (en) 2015-04-20 2015-06-03 Ucl Business Plc T cell receptor
PL3298033T5 (pl) 2015-05-18 2023-10-30 TCR2 Therapeutics Inc. Kompozycje i zastosowania medyczne do reprogramowania TCR z zastosowaniem białek fuzyjnych
EP3095792A1 (en) 2015-05-19 2016-11-23 Klinikum rechts der Isar der Technischen Universität München T cell receptor with specificity for myeloperoxidase peptide and uses thereof
MX2018004721A (es) 2015-10-23 2018-07-06 Eureka Therapeutics Inc Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas.
GB201522592D0 (en) 2015-12-22 2016-02-03 Immunocore Ltd T cell receptors
GB201604458D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
GB201604492D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
CN116731156A (zh) 2016-03-16 2023-09-12 伊玛提克斯生物技术有限公司 用于癌症免疫治疗的转染t细胞和t细胞受体
US11446398B2 (en) 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems
CA3032498A1 (en) 2016-08-02 2018-02-08 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
WO2018026018A1 (ja) 2016-08-05 2018-02-08 国立大学法人東北大学 Ｔ細胞受容体の認識機構を用いたがん又は感染症の治療及び診断
GB201617716D0 (en) 2016-10-19 2016-11-30 Ucl Business Plc Cell
GB201617714D0 (en) 2016-10-19 2016-11-30 Ucl Business Plc T Cell receptor
DE102016121899A1 (de) 2016-11-15 2018-05-17 Immatics Biotechnologies Gmbh Verfahren zur Herstellung von elektrokompetenten Hefezellen und Verfahren zur Verwendung dieser Zellen
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
WO2018226931A1 (en) * 2017-06-07 2018-12-13 David Weiner Mage-a vaccines and methods of treatment using the same
LT3428194T (lt) 2017-07-14 2021-12-10 Immatics Biotechnologies Gmbh Pagerinta dvejopo savitumo polipeptido molekulė
DE102017127984B4 (de) 2017-11-27 2019-12-05 Immatics US, Inc. Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen
DE102018100967B4 (de) 2018-01-17 2019-08-14 Immatics US, Inc. Verfahren zur feststellung der wirksamkeit von viralen vektoren
EP3747456A4 (en) 2018-01-31 2021-12-01 Tohoku University PROCESS FOR REGULATING THE EXPRESSION OF THE SPECIFIC MHC OF AN ANTIGEN
BR112020016176A2 (pt) 2018-02-09 2022-02-22 Immatics Us Inc Métodos de transdução de uma célula t, célula t transduzida geneticamente, composição farmacêutica, métodos de preparação de uma população de células t e uso da célula t
DE102018108612A1 (de) 2018-03-21 2019-09-26 Immatics US, Inc. Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
KR20210010896A (ko) 2018-05-14 2021-01-28 이뮤노코어 리미티드 이기능성 결합 폴리펩타이드
CA3102254A1 (en) 2018-06-04 2019-12-12 Apo-T B.V. Methods and means for attracting immune effector cells to tumor cells
GB201819540D0 (en) 2018-11-30 2019-01-16 Adaptimmune Ltd T cell modification
AU2020209991B2 (en) 2019-01-17 2024-11-14 Immunocore Limited Formulations
GB201901306D0 (en) 2019-01-30 2019-03-20 Immunocore Ltd Multi-domain binding molecules
CN118994397A (zh) 2019-05-21 2024-11-22 诺华股份有限公司 针对bcma的三特异性结合分子及其用途
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
DE102019121007A1 (de) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
GB201911286D0 (en) 2019-08-07 2019-09-18 Ucl Business Plc Method
CN114729305A (zh) 2019-10-17 2022-07-08 苏州丹罗医药有限公司 用于免疫治疗的嵌合抗原受体、制备方法及其应用
IL308258A (en) 2021-05-05 2024-01-01 Immatics Biotechnologies Gmbh Bma031 antigen binding polypeptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
1. S. Daudi, u. a.: Expression and immune responses to MAGE antigens predict survival in epithelial ovarian cancer 2014 In: PLOS ONE, Volume 9, Issue 8, e104099 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230365649A1 (en) * 2020-10-02 2023-11-16 The Usa, As Represented By The Secretary, Department Of Health And Human Services Hla class ii-restricted dq t cell receptors against ras with g13d mutation
WO2023148494A1 (en) * 2022-02-03 2023-08-10 University College Cardiff Consultants Limited Novel t-cell receptor

Also Published As

Publication number Publication date
US20210032361A1 (en) 2021-02-04
AR120585A1 (es) 2022-02-23
MX2022001422A (es) 2022-03-29
EP4007776A1 (en) 2022-06-08
US11840577B2 (en) 2023-12-12
CA3148937A1 (en) 2021-02-11
BR112022001923A2 (pt) 2022-03-29
JP2024105296A (ja) 2024-08-06
CR20220086A (es) 2022-05-05
WO2021023658A1 (en) 2021-02-11
PE20221021A1 (es) 2022-06-16
CL2023000562A1 (es) 2023-08-04
JP2022541349A (ja) 2022-09-22
AU2020324515A1 (en) 2022-02-24
KR20220041161A (ko) 2022-03-31
US20240117068A1 (en) 2024-04-11
US20250215084A1 (en) 2025-07-03
TWI878330B (zh) 2025-04-01
US20240052054A1 (en) 2024-02-15
CN114616244A (zh) 2022-06-10
CL2022000252A1 (es) 2022-09-09
JP7476298B2 (ja) 2024-04-30
CO2022002044A2 (es) 2022-06-10
US12269881B2 (en) 2025-04-08
PH12022550230A1 (en) 2023-01-04
MX2022011410A (es) 2022-10-13
MX2022011411A (es) 2022-10-13
TW202120548A (zh) 2021-06-01
IL290268A (en) 2022-04-01
CN115925958A (zh) 2023-04-07

Similar Documents

Publication Publication Date Title
TWI878330B (zh) 特異性結合mage-a的抗原結合蛋白
US20230203200A1 (en) Recruiting agent further binding an mhc molecule
US11859009B2 (en) Antigen binding proteins specifically binding PRAME
KR20260047511A (ko) Mageb2에 대한 항원 결합 단백질
DE102019121022A1 (de) Rekrutierungsagens, das zusätzlich ein MHC-Molekül bindet
US20250034227A1 (en) Antigen binding proteins against mageb2
HK40091509A (zh) 特异性结合mage-a的抗原结合蛋白
EA049528B1 (ru) Антигенсвязывающие белки, специфически связывающие mage-a

Legal Events

Date Code Title Description
R012 Request for examination validly filed
R016 Response to examination communication